Health  Vol.7 No.11 , November 2015
Community Pharmacists’ Strategies in Greece: An Assessment of the Policy Environment and the Mapping of Key Players
Abstract: The aim of the study was to form and assess the pharmacists’ strategies in Greece, by analyzing the policy environment and identifying the role of the key players-stakeholders. For collecting and organizing important information about the pharmacists’ policy, the PolicyMaker’s computerized version of political mapping was used, serving as a database for assessments of the policy’s content, the major players, the power and policy positions of key players, the interests of different players, and the networks and coalitions that connect the players. As the research findings show, the initially expected impact of the pharmacists’ policy proved to be very optimistic in most of the implemented strategies, as the majority of the strategies have worsened or minimized their success ratio throughout the time in study. Concluding, either the initially set strategies were at the wrong direction or the actions taken to implement them were inappropriate. Moreover, one can suggest that the shifting ability in both the position and the power of the most key players were over-estimated, while they under-estimated the impact of troika-constitutions meddling in the pharmaceutical policymaking and in the health sector cost-containment measures imposing.
Cite this paper: Vozikis, A. , Stavropoulou, L. and Patrinos, G. (2015) Community Pharmacists’ Strategies in Greece: An Assessment of the Policy Environment and the Mapping of Key Players. Health, 7, 1560-1577. doi: 10.4236/health.2015.711170.

[1]   Eurostat (2013) EU Unemployment Data. Brussels.

[2]   European Commission (EC) (2013) The Second Economic Adjustment Programme for Greece: Third Review. European Economy, Occasional Papers 159, European Commission, Directorate-General for Economic and Financial Affairs. Brussels.

[3]   World Health Organization (WHO) (2012) European Health Report. Geneva.

[4]   Kanellopoulou, S. (2013) Policies to Contain Public Pharmaceutical Expenditure by Acting Not Only on the Supply-Side but on the Demand Side as Well. Eurobank Economic Research, Greece Macro-Monitor, Focus Notes: Greece, Athens.

[5]   Hellenic Association of Pharmaceutical Companies (SFEE) (2012) The Pharmaceutical Market in Greece_Facts and Figures. Athens.

[6]   Foundation for Economic and Industrial Research (IOBE) (2013) Annual report for the Pharma-Industry 2012. Athens.

[7]   Ministry of Finance (MOF) (2013) Medium-Term Fiscal Strategy 2013-2016. Athens.

[8]   Hellenic Association of Pharmaceutical Companies (SFEE) (2013) A Trip without Compass. Athens. (In Greek)

[9]   Pharmaceutical Group of European Union (PGEU) (2012) Advancing Community Pharmacy Practice in Challenging Times, Annual Report 2012. Brussels.

[10]   Kanellopoulou, S. (2012) Health Sector Reforms and the Memorandum of Understanding. Eurobank Economic Research, Greece Macro-Monitor, Focus Notes: Greece, Eurobank Research, Athens.

[11]   Roberts, A., Benrimoj, S.I., Dunphy, D. and Palmer, I. (2007) Community Pharmacy: Strategic Change Management. McGraw-Hill Australia Pty Ltd, Sydney.

[12]   Gidman, W. (2010) Exploring the Impact of Evolving Health Policy on Independent Pharmacy Ownership in England. Springer Science & Business Media B.V., Netherlands.

[13]   McArthur, D. (2007) European Pharmaceutical Distribution: Key Players, Challenges and Future Strategies. Scrip Reports, Informa UK Ltd., London.

[14]   Mossialos, E. and Allin, S. (2005) Interest Groups and Health System Reform in Greece. West European Politics, 28, 420-444.

[15]   McMillan, S.S., Wheeler, J.A., Sav, A., King, A.M., Whitty, A.J., Kendall, E. and Kelly, F. (2013) Community Pharmacy in Australia: A Health Hub Destination of the Future. Research in Social and Administrative Pharmacy, 9, 863-875.

[16]   Reich, M.R. (1996) Applied Political Analysis for Health Policy Reform. Current Issues in Public Health, 2, 186-191.

[17]   Reich, M.R. and Cooper, D.M. (1996) PolicyMaker: Computer-Assisted Political Analysis (Software and Manual). PoliMap, Newton Centre.

[18]   Glassman, A., Reich, M.R., Laserson, K. and Rojas, F. (1999) Political Analysis of Health Reform in the Dominican Republic. Health Policy and Planning, 14, 115-126.

[19]   Mintzberg, H. (1994) The Rise and Fall of Strategic Planning. Free Press, New York.

[20]   Armstrong, M., Lewis, R., Blenkinsopp, A. and Anderson, C. (2005) The Contribution of Community Pharmacy to Improving the Public’s Health. Report 3: An Overview of the Evidence-Base from 1990-2002 with Recommendations for Action. Pharmacy Health Link and the Royal Pharmaceutical Society of Great Britain, London.

[21]   Kontozamanis, V., Mantzouneas, E. and Stoforos, C. (2003) An Overview of the Greek Pharmaceutical Market. European Journal of Health Economics, 4, 327-333.

[22]   Lluch, Μ.M. and Kanavos, P. (2010) Impact of Regulation of Community Pharmacies on Efficiency, Access and Equity. Evidence from the UK and Spain. Health Policy, 95, 245-254.

[23]   Pharmaceutical Group of European Union (PGEU) (2010) Providing Quality Pharmacy Services to Communities in Times of Change, Annual Report 2010. Brussels.

[24]   Pharmaceutical Group of European Union (PGEU) (2012) European Community Pharmacy Blueprint for Optimisation of Health Outcomes to Individual Patients and Value for Health Systems across Europe. Brussels.

[25]   Pharmacy Voice (2011) Community Pharmacy: A Blueprint for Better Health. London.

[26]   Pharmacy Voice (2012) Community Pharmacy: Our Prospectus for Better Health. Pharmacy Voice Limited, London.

[27]   Sainsbury’s Pharmacy (2013) The Wells Family Challenge: A Pharmacist First Approach. Collated and Evaluated by 2020 Health, Sainsbury’s Co., UK.

[28]   Twigg, J.M., Poland, F., Bhattacharya, D., Desborough, A.J. and Wright, J.D. (2013) The Current and Future Roles of Community Pharmacists: Views and Experiences of Patients with Type 2 Diabetes. Research in Social and Administrative Pharmacy, 9, 777-789.

[29]   Moullin, J.C., Sabater-Hernandez, D., Fernandez-Llimos, F. and Benrimoj, S.I. (2013) Defining Professional Pharmacy Services in Community Pharmacy. Research in Social and Administrative Pharmacy, 9, 989-995.

[30]   European Commission, EC (2010) The Economic Adjustment Programme for Greece, European Economy. Occasional Papers 61, European Commission, Directorate-General for Economic and Financial Affairs, Brussels.

[31]   OECD (2013) OECD Health Data 2013, OECD Health Statistics (Database). Paris.

[32]   Von der Schulenburg, G. and Hodek, J.M. (2008) Costs and Benefits of Pharmacy Regulation in Germany. Proceedings of the Workshop on Access to High Quality Pharmacy Services, Brussels, 15 October 2008.

[33]   Lluch, M. (2009) Are Regulations of Community Pharmacies in Europe Questioning Our Pro-Competitive Policies? Eurohealth, 15, 26-27.

[34]   Vogler, S., Arts, D. and Sandberger, K. (2012) Impact of Pharmacy Deregulation and Regulation in European Countries. Commissioned by Danmarks Apotekerforening (Association of Danish Pharmacies), Gesundheit Osterreich GmbH., Vienna.

[35]   Business Concept (2012) Pharmacy Feasibility Study. Business Concept Supply Chain, Athens. (In Greek)

[36]   Wiedenmayer, K., Summers, S.R., Mackie, A.C., Gous, G.S.A., Everard, M. and Tromp, D. (2006) Developing Pharmacy Practice: A Focus on Patient Care, Handbook—2006 Edition. World Health Organization, Department of Medicines Policy and Standards, Geneva, Switzerland in Collaboration with International Pharmaceutical Federation, The Hague.

[37]   Brown, D., Portlock, J., Rutter, P. and Nazar, Z. (2014) From Community Pharmacy to Healthy Living Pharmacy. Research in Social and Administrative Pharmacy, 10, 72-87.

[38]   Deloitte UK, CFHS (2013) Impact of Austerity on European Pharmaceutical Policy and Pricing: Staying Competitive in a Challenging Environment. Deloitte UK Centre for Health Solutions, London.

[39]   Department of Health, Social Services and Public Safety (DHSSPSNI) (2013) Making It Better through Pharmacy in the Community. Consultation on Proposals for a Five Year Strategy for Pharmacy in the Community, UK.

[40]   Giberson, S., Yoder, S. and Lee, M.P. (2011) Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the US Surgeon General, Office of the Chief Pharmacist, US Public Health Service, Rockville.

[41]   Pharmaceutical Group of European Union (PGEU) (2012) Sustainable European Community Pharmacies Part of the Solution. Brussels.

[42]   ABDA—Federal Union of German Associations of Pharmacists (2012) German Pharmacies Figures Data Facts. Berlin.

[43]   Bush, J., Langley, A.C. and Wilson, A.K. 2009) The Corporatization of Community Pharmacy: Implications for Service Provision, the Public Health Function, and Pharmacy’s Claims to Professional Status in the United Kingdom. Research in Social and Administrative Pharmacy, 5, 305-318.

[44]   Harrison, J., Scahill, S. and Sheridan, J. (2012) New Zealand Pharmacists’ Alignment with Their Professional Body’s Vision for the Future. Research in Social and Administrative Pharmacy, 8, 17-35.

[45]   Lindberg, K., Nicolini, D., Adolfsson, P., Bergamaschi, M., Delmestri, G., Goodrick, E. and Reay, T. (2008) Exploring the Globalized Face of Pharmacy. In: Academy of Management “The Questions We Ask”, Anaheim.

[46]   Perepelkin, J. and Manfrin, A. (2012) Pharmacist Service Provision and the Environment of the Community Pharmacy in Canada. Research in Social and Administrative Pharmacy, 8, e53-e54.

[47]   Doucette, R.W., Nevins, C.J., Gaither, C., Kreling, H.D., Mott, A.D., Pedersen, A.C. and Schommer, C.J. (2012) Organizational Factors Influencing Pharmacy Practice Change. Research in Social and Administrative Pharmacy, 8, 274-284.

[48]   NHS Lothian (2013) Pharmacy Strategy 2013-2016. Scotland.

[49]   Center for Health Services Management and Evaluation (CHESME) (2001) Expenditure on Pharmaceuticals and the Organizational and Operational Framework of Pharmacies in Greece and the EU. National and Kapodistrian University, Athens.

[50]   Co-Operatives Europe (2009) Mapping Exercise: Co-Operatives Working in the Pharmacy Sector in Europe, European Seminar: Cooperative Enterprises in the Pharmacy Sector, Opportunities & Challenges. European House of Co-Operatives, Brussels.

[51]   Eyeforpharma (2012) Austerity Agenda Increases Pressure on Pharma Companies to Adopt KAM for Managing Burgeoning Stakeholder Challenges. Eyeforpharma KAM Report 2011/2012, Eyeforpharma, FC Business Intelligence Ltd., London.

[52]   Kanavos, P., Vandoros, S., Irwin, R., Nicod, E. and Casson, M. (2011) Differences in Costs of and Access to Pharmaceutical Products in the EU. European Parliament’s Committee on Environment, Public Health and Food Safety, D.G. for Internal Policies, Policy Department, Economic and Social Policy, Brussels.

[53]   Manhattan Research (2012) Taking the Pulse? Pharmacists 2012: Pharmacist Market Trends. Manhattan Research, New York.

[54]   National Pharmacy Association (2012) Community Pharmacy Statistics 2012.

[55]   Sheppard, A. (2010) Generic Medicines: Essential Contributors to the Long-Term Health of Society, Sector Sustainability Challenges in Europe. IMS Health, London.

[56]   Schommer, C.J., Yusuf, A.A. and Hadsall, S.R. (2013) Market Dynamics of Community Pharmacies in Minnesota, US from 1992 through 2012. Research in Social and Administrative Pharmacy, 10, 217-231.